ESC Professional Premium Access

Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

Congress Presentation

About the speaker

Doctor Steven Deitelzweig

Ochsner Medical Center, New Orleans (United States of America)
7 presentations
0 follower

7 more presentations in this session

Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study

Speaker: Doctor M. Abou Kaoud (Tel Aviv, IL)

Thumbnail

Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

Speaker: Mr M. Grymonprez (Ghent, BE)

Thumbnail

Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

Speaker: Doctor S. Patel (Boston, US)

Thumbnail

Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients

Speaker: Doctor J. Kim (Seoul, KR)

Thumbnail

Access the full session

Oral anticoagulation in patients with atrial fibrillation

Speakers: Doctor S. Deitelzweig, Doctor M. Abou Kaoud, Mr M. Grymonprez, Doctor S. Patel, Doctor T. Chao...
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

ESC 365 is supported by